Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension

Abstract

The purpose of this first prospective observational cohort study after launch was to document the efficacy and tolerability of therapy with the fixed combination of lercanidipine HC1 (CAS 132866-11-6), a third-generation calcium antagonist, and the angiotensin converting enzyme (ACE) inhibitor enalapril maleate (CAS 76095-16-4) in patients with essential hypertension in daily practice. Both parts of the observational study were conducted with the fixed combination of enalapril maleate 10 respectively 20 mg and lercanidipine HC1 10 mg, one part with Zaneril® and the other with Zanipress®. The fixed combination is marketed under these product names in Germany.

The data of 8,440 patients with a mean age of 62 years and a mean body mass index (BMI) of 28 kg/m² were evaluated. 84% of the patients had already received pre-treatment for essential hypertension. 26% of all the patients were known to have had hypertension for at least 10 years. Around 70% had further concomitant diseases.

The mean blood pressure before the beginning of the study was 162.5/94.5 mmHg, the mean reduction after around three months was 28.4/13.5 mmHg. Just under 80% of the patients reached the desired target blood pressure after the observation period.

The global assessment of the physicians shows that the efficacy of the drugs was “very good” to “good” for 94% of the patients. Global tolerability was assessed as “very good” and “good” for 97% of the patients. Compliance was stated as “very good” and “good” for 97% of the patients. Adverse drug reactions were documented for 2% of all patients.

Key words

Antihypertensive fixed combination - Enalapril - Essential hypertension - Lercanidipine - Zaneril® - Zanipress®

• References

• 1 Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA. 2003; 14; 289 (18) 2363-9
• 2 Büchner N, Vonend O, Rump LC. Pathophysiology of hypertension; what’s new?. Herz 2006; Jun 31 (4) 294-302
• 3 Leitlinien zur Diagnostik und Behandlung der Hypertonic [Internet]. Deutsche Hochdruckliga e.V. – Deutsche Hypertonic Gesellschaft; 2008 June 1. Available from: http://www.hochdruckliga.de/guideline.htm
• 4 Manica G, De Becker G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105-87
• 5 Manica G, Laurent S, Agabiti-Rosei E, Ambrosiani E, Burnier M, Caulfield MJ et al. Reapprasial of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertension. 2009; 22 ahead of print.
• 6 The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) 2007 Guidelines for the management of arterial hypertension. Eur Heart J. 2007; 28: 1462-536
• 7 Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; Dec 4 359 (23) 2417-28
• 8 Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs. 2003; 63 (22) 2449-72
• 9 Lund-Johansen P, Stranden E, Helberg S, Wessel-Aas T, Risberg K, Ronnevik PK et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J. Hypertension. 2003; May 21 (5) 1003-10
• 10 Aktories K, Förstermann U, Hoffmann FB, Starke K. Allge-meine und spezielle Pharmakologie und Toxikologie. Munich: Urban&Fischer Verlag; 2008
• 11 Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P et al. Effect of lercanidipine compared with ra-mipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (dia-bete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab. 2004; Oct 17 (5) 259-66
• 12 Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998; 97 (14) 1411-20
• 13 Grassi G, Quarti-Trevano F, Scopelliti F, Seravalle G, Cuspidi C, Mancia G. Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes. Blood Press. 2006; 15 (5) 268-74
• 14 Leu HB, Charng MJ, Ding PY. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension. Jpn Heart J. 2004; Jul 45 (4) 623-35
• 15 Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Empfehlung zur Planung und Durchführung von Anwendungsbeobachtungen. Bundesanzeiger Nr. 229 dated 04.12.1998, S. 16884.
• 16 Summary of Product Characteristics Zaneril®, July 2006; Summary of Product Characteristics Zanipress®, September 2008
• 17 Puig JG, Calvo C, Luurila O, Luurila H, Sulosaari S, Strandberg A et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens. 2007; 21 (12) 917-24
• 18 Hair PI, Scott LJ, Perry CM. Fixed Dose Combination Ler-canidipine/Enalapril. Drugs. 2007; 67 (1) 95-106